The study, MOSA1c, will be the first major international prospective observational assessment of the real-world obstacles met by type 2 diabetes patients in reaching their ideal blood sugar targets, which can put them at risk of serious complications.
Around 4,500 subjects from the US and 16 other countries will be followed for two years, with the aim of shedding light on treatment barriers, enhancing communication with physicians and helping patients engage with their own treatment better.
Brigham and Women's Hospital and Harvard Medical School will be assisting Lilly in conducting the study, interim results from which will be available in mid-2012.
Dr Robert Heine, vice-president for medical affairs at Lilly Diabetes, said: "We understand that type 2 diabetes is influenced by behaviours that, if understood, could be adapted for improved management of the disease."
This comes after Lilly launched a new treatment for type 2 diabetes mellitus called Trajenta in the UK, in association with partner Boehringer Ingelheim.
Around 4,500 subjects from the US and 16 other countries will be followed for two years, with the aim of shedding light on treatment barriers, enhancing communication with physicians and helping patients engage with their own treatment better.
Brigham and Women's Hospital and Harvard Medical School will be assisting Lilly in conducting the study, interim results from which will be available in mid-2012.
Dr Robert Heine, vice-president for medical affairs at Lilly Diabetes, said: "We understand that type 2 diabetes is influenced by behaviours that, if understood, could be adapted for improved management of the disease."
This comes after Lilly launched a new treatment for type 2 diabetes mellitus called Trajenta in the UK, in association with partner Boehringer Ingelheim.